Metformin-Based Combination Approaches for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Metabolic Diseases

Background:

• Diabetes and cancer share significant correlations, prompting research into anti-diabetic drugs like metformin for cancer treatment.
• Metformin exhibits anticancer properties, particularly against breast cancer, a leading cause of mortality in women.
• Triple-negative breast cancer (TNBC) presents a poor prognosis with limited treatment options due to the absence of hormone receptors and HER2, and frequent resistance development.

Purpose of the Study:

• To review recent mechanistic insights and efficacy of metformin and metformin-based therapies for TNBC treatment.
• To discuss experimental evidence on metformin's effects on metabolic pathways and its combination therapies for TNBC.

Main Methods:

• Review of in vitro and in vivo studies on metformin's effects on cancer cell proliferation, invasion, migration, and apoptosis.
• Analysis of studies combining metformin with other therapeutic agents targeting cell signaling pathways.
• Examination of approaches to enhance metformin's efficacy and review of clinical studies in TNBC patients.

Main Results:

• Metformin targets key cancer-related characteristics including cell proliferation, invasion, migration, and apoptosis.
• Metformin-based combination therapies show potential in targeting specific signaling pathways and enhancing treatment effects.
• Clinical studies indicate beneficial outcomes for TNBC patients treated with metformin or its combinations.

Conclusions:

• Metformin demonstrates significant potential as an anticancer agent, particularly for triple-negative breast cancer.
• Combination strategies and enhanced delivery methods may improve metformin's efficacy in TNBC treatment.
• Further clinical investigation is warranted to fully establish metformin's role in TNBC therapy.